Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics' stock price has been influenced by several events in the past six months. A surge occurred in September 2025 due to a rival company's hypertension data falling short. Positive Phase 3 hypertension trial results also led to a share price increase earlier in 2025. A third-quarter earnings beat in November 2025 was positively received. The company plans to submit a New Drug Application (NDA) for lorundrostat by late 2025 or early 2026. However, insider selling and broader biotech sector weakness caused declines in January 2026. Despite pullbacks, the stock has increased by 185.60% over the last year.

As a clinical-stage biopharmaceutical company without commercialized products, Mineralys Therapeutics does not experience traditional demand seasonality. Demand for lorundrostat will depend on regulatory approval and market adoption, not seasonal fluctuations.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by abnormally elevated aldosterone. Their primary product candidate is lorundrostat, an orally administered aldosterone synthase inhibitor, being developed for cardiorenal conditions like hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company has completed Phase 2 proof-of-concept studies and pivotal Phase 2 and Phase 3 trials for lorundrostat in hypertension, and is also conducting proof-of-concept studies for CKD and OSA.

Mineralys Therapeutics, Inc. was incorporated in Delaware in May 2019 and is headquartered in Radnor, Pennsylvania. The company's development efforts for medicines targeting dysregulated aldosterone are focused within the United States.

Mineralys Therapeutics has built a positive brand reputation through strong clinical trial results and scientific recognition. Lorundrostat's promising trial results for hypertension support its potential for FDA approval. Positive findings from pivotal trials have been presented at conferences and published in journals, enhancing credibility. Analyst sentiment is constructive, with buy ratings and price targets above current levels. A survey indicated strong potential market acceptance, and the company is expanding its medical communications team.

Mineralys Therapeutics, Inc. has a substantial institutional ownership base, with 316 institutional owners and shareholders holding a total of 86,945,388 shares. Major institutional owners include Catalys Pacific, LLC, Ra Capital Management, L.p., Samsara BioCapital, LLC, BlackRock, Inc., Vanguard Group Inc, SMCWX - SMALLCAP WORLD FUND INC Class A, Caligan Partners LP, Capital International Investors, Suvretta Capital Management, Llc, and Sr One Capital Management, Lp. As of December 31, 2025, FMR LLC and Abigail P. Johnson also reported beneficial ownership of 5,017,509 shares, representing 6.3% of the company's outstanding common stock.